Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Magdalini Migkou
Honoraria: Janssen, GlaxoSmithKline
Maria Gavriatopoulou
Honoraria: Amgen, Janssen, Celgene, Takeda
Consulting or Advisory Role: Amgen, Karyopharm Therapeutics
Research Funding: Novartis
Travel, Accommodations, Expenses: Takeda, Genesis Pharma, Janssen
Efstathios Kastritis
Honoraria: Amgen, Genesis Pharma, Janssen Oncology, Takeda, Prothena, Pfizer, GlaxoSmithKline
Consulting or Advisory Role: Amgen, Janssen Oncology, Takeda, Genesis Pharma, Prothena, Pfizer
Research Funding: Janssen Oncology (Inst), Amgen (Inst)
Travel, Accommodations, Expenses: Janssen Oncology, Genesis Pharma, Takeda, Pfizer
Evangelos Terpos
Honoraria: Amgen, Celgene, Takeda, Janssen-Cilag, Bristol Myers Squibb, Genesis Pharmaceuticals, Sanofi, Novartis, GlaxoSmithKline
Consulting or Advisory Role: Takeda, Janssen-Cilag, Amgen, Celgene, Genesis Pharmaceuticals, Sanofi, GlaxoSmithKline
Research Funding: Amgen (Inst), Janssen-Cilag (Inst), Genesis Pharmaceuticals (Inst), Takeda (Inst), Sanofi (Inst), GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses: Amgen, Takeda
Meletios-Athanasios Dimopoulos
Honoraria: Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, Beigene
Consulting or Advisory Role: Amgen, Janssen-Cilag, Takeda, Bristol Myers Squibb, Beigene
No other potential conflicts of interest were reported.
Comments (0)